FRAMINGHAM, Mass. and SYDNEY, April 12, 2011 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ: HTWR - ASX: HIN), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that the HeartWare® Ventricular Assist System will be the subject of presentations at The International Society of Heart and Lung Transplantation (ISHLT) 31st Annual Meeting and Scientific Sessions, April 13-16 in San Diego.
During ISHLT, multiple oral sessions, posters and presentations will detail experience with the HeartWare® Ventricular Assist System, which features the HVAD® pump. Most notably, at 4:00 pm Pacific (7:00 pm ET) on Friday, April 15, Principal Investigator for HeartWare's bridge-to-transplant study ADVANCE, Mark S. Slaughter, M.D., Professor and Chief in the Division of Thoracic and Cardiovascular Surgery and Director of the Mechanical Assist Device and Heart Transplant Program at the University of Louisville, will provide an update to clinical data from ADVANCE, as well as from the Continued Access Protocol for that study.
"For the past three years, the number of HVAD-related presentations at ISHLT has risen rapidly, reflecting broad and growing support among our international commercial sites and interest from our clinical trial sites in the U.S. The diversity of these presentations reflects the versatility of our device and, importantly, forums like ISHLT provide our customers with an excellent opportunity to share their global experiences with the HVAD. The growing interest and support is also evidenced by the fact that more than 1,000 advanced heart failure patients have now received the HVAD pump – an important milestone for our Company," explained Doug Godshall, President and Chief Executive Officer. "Today we have 54 internat